



## Neurodevelopmental Disorders: From Pathophysiology to Treatment

Collection Editors:

**Dr. Nader Perroud**

**Dr. Markus Mathaus Kosel**

**Dr. Gaelle E. Doucet**

### Message from the Collection Editors

Dear Colleagues,

DSM-5, introduced in 2013, allowed a renewed appreciation of the longitudinal, whole-life perspective of neurodevelopmental disorders in psychiatry including autism spectrum disorder (ASD) and other communication, speech and language disorders, attention-deficit/hyperactivity disorder (ADHD), intellectual disability (ID) as well as other specific learning disorders.

However, our understanding of the basic aspects of the pathophysiology of these disorders and efficient therapies is still incomplete. The adult population suffering from these disorders is also widely underresearched and thus rarely benefit from adequate treatments.

In this Topical Collection of *Biomedicines*, we aim to present to the journal readers the actual state of the art in the understanding of the pathophysiology of neurodevelopmental disorders and their treatments, from birth to the end of life.

Dr. Nader Perroud  
Dr. Markus Mathaus Kosel  
*Collection Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)